REG - Diaceutics PLC - Block Listing Return

DiaceuticsAnnouncement

07/04/2025 10:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250407:nRSG9202Da&default-theme=true

RNS Number : 9202D  Diaceutics PLC  07 April 2025

Diaceutics PLC

 

BLOCK LISTING RETURN

 

New York, Belfast and London, 7 April 2025 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, gives the below information
required by Schedule 6 of the AIM Rules for Companies in connection with the
UK and Global Share Incentive Plan for employees (the "SIP") and the Employee
Share Option Plan (the "ESOP") which includes long-term incentive awards.

 

 Name of applicant:                                                              Diaceutics PLC
 Name of scheme:                                                                 UK and Global Share Incentive Plan for employees (the "SIP") and the Employee
                                                                                 Share Option Plan (the "ESOP") which includes long-term incentive awards.
 Period of return:                       From:                                   7 October 2024              To:                         6 April 2025
 Balance under scheme from previous return:                                      1,423,411 Ordinary Shares of £0.002 each
 The amount by which the block scheme has been increased, if the scheme has      N/A
 been increased since the date of the last return:
 Number of securities issued/allotted under schemes during period:               71,443 Ordinary Shares

 Balance under scheme not yet issued/allotted at end of period                   1,351,968 Ordinary Shares
 Number and class of securities originally listed and the date of admission      1,500,000 Ordinary Shares on 6 October 2023
 Total number of securities in issue at the end of the period                    84,798,378 Ordinary Shares of £0.002 each
 Name of contact:                                                                Nick Roberts
 Telephone number of contact:                                                    As below

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRFIFVASLIDIIE